Report Categories
View AllRecent Articles
View All
Regeneron Pharmaceuticals REGN Otarmeni Gene Therapy Launch Shifts LongTerm Narrative Amid Pipeline Execution Focus
SLNO Soleno Therapeutics tops Q4 2025 EPS estimates by 103 percent shares edge 021 percent lower today
MCN XAI management lays out targeted premium income fund growth strategies after latest quarterly earnings release